Pepgen reports positive data from phase 1 trial of pgn-edo51 for the treatment of duchenne muscular dystrophy

- pgn-edo51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches -
PEPG Ratings Summary
PEPG Quant Ranking